Neuropore Therapies and UCB have entered into a world-wide collaboration and agreement to develop and commercialize therapeutic products aiming at slowing the progression of Parkinson’s disease and related disorders.
This includes NPT200-11, Neuropore’s novel small molecule that targets pathogenic alpha-synuclein which is currently in preclinical development and is expected to enter clinical Phase 1 in 2015.
|Searching for more deal information? Current Partnering offers the following options:
UCB will receive the world-wide exclusive license to develop and commercialize NPT200-11 in all indications. UCB and Neuropore will work together to complete non-clinical studies, and a first Phase 1 study to be initiated in 2015.
UCB will lead all further clinical development, regulatory activities and commercialization.
Neuropore will receive an initial upfront payment of US$20 million and is entitled to potential development, regulatory and sales-based milestones payments, of up to a potential total of US$460 million, in addition to royalties on net sales.
Financial details of the agreement were not disclosed.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2014
View: Top biotech companies